Summary:
Exciting collaboration between pharmaceutical giants Takeda and Janssen with wearable device maker Actigraph. The project, DECODE, aims to validate a digital measure quantifying nighttime scratching in people with skin conditions like psoriasis and atopic dermatitis. This innovative approach could serve as an endpoint in clinical trials for new drugs targeting these conditions. Approximately 60 participants will be monitored using infrared cameras and Actigraph devices during sleep to develop an algorithm accurately discerning nighttime scratching. Takeda’s interest in this potential endpoint is tied to their drug candidate, TAK-279, for psoriasis treatment.
The study will involve approximately 60 participants with skin conditions, who will be monitored using infrared cameras and Actigraph devices while they sleep. The data collected will be used to develop an algorithm that can accurately discern nighttime scratching. Actigraph hopes to have a provisional algorithm by the end of next year, with the project expected to be completed by the first half of 2025.
Article written by Tech Desk| Image by Istock
30/11/2023
Source:
Compsmag
https://www.cataloniabioht.org/news/la-plataforma-neural-intel-ligent-de-grafe-dinbrain-rep-la-breakthrough-device-designation-de-la-fda/?lang=en